AB Science S.A. (FRA:A8D)

Market Cap	97.60M -5.2%
Revenue (ttm)	1.03M -5.1%
Net Income	-8.54M
EPS	-0.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Average Volume	25
Open	1.312
Previous Close	1.280
Day's Range	1.312 - 1.312
52-Week Range	1.050 - 1.686
Beta	n/a
RSI	44.54
Earnings Date	May 7, 2026

About AB Science

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A8D

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.